Mechanism insights into the pleiotropic effects of nobiletin as a potential therapeutic agent on non-alcoholic fatty liver disease (NAFLD)

被引:1
|
作者
Ran, Qiqi [1 ]
Gan, Qianrong [1 ]
Zhu, Ye [2 ]
Song, Li [1 ]
Shen, Longyu [1 ]
Duan, Xinyi [1 ]
Zhu, Xinyun [3 ]
Huang, Wei [1 ]
机构
[1] Chengdu Univ Tradit Chinese Med, Sch Basic Med Sci, Chengdu 611137, Peoples R China
[2] Hainan Med Univ, Dept Tradit Chinese Med, Affiliated Hosp 1, Hainan 570102, Peoples R China
[3] Chengdu Univ Tradit Chinese Med, Chengdu 611137, Peoples R China
基金
美国国家科学基金会;
关键词
Non-alcoholic fatty liver disease; Nobiletin; Lipid metabolism; Insulin resistance; Anti-inflammatory; Anti-oxidation; CITRUS FLAVONOIDS; OXIDATIVE STRESS; PATHOGENESIS; CHOLESTEROL; INFLAMMATION; METABOLITES; INSULIN; CELLS; 4'-DEMETHYLNOBILETIN; 5-DEMETHYLNOBILETIN;
D O I
10.1016/j.biopha.2024.116322
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases and is emerging as one of the fastest-growing causes of liver-related deaths worldwide. It is necessary to find strategies to effectively prevent and treat NAFLD, as no definitive drug has been approved. Nobiletin (NOB) is the critical active ingredient of Chinese herbal medicines such as Citrus aurantium and Citri Reticulatae Pericarpium, which have antiinflammatory, antioxidant, lipid regulating, and insulin resistance regulating effects. Numerous studies have demonstrated that NOB can prevent and treat the onset and progression of NAFLD. In this review, the mechanisms of NOB for treating NAFLD have been summarized, hoping to provide a basis for subsequent studies of NOB and to provide a research ground for the development of therapeutic drugs for NAFLD.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Prevalence of non-alcoholic fatty liver disease (NAFLD) in Singapore
    Tan, H. H.
    Chang, J. P. E.
    Chin, C.
    Tan, C. K.
    Lui, H. F.
    Chow, W. C.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A444 - A445
  • [32] NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND RESPIRATORY FUNCTIONS
    Ozkarafakili, Mufide Arzu
    Ga, Salih Bo
    Ozguven, M. Banu Yilmaz
    RESPIROLOGY, 2018, 23 : 198 - 198
  • [33] Non-alcoholic Fatty Liver Disease Diagnosis and Therapy of NAFLD
    Canbay, Ali
    Lammert, Frank
    Geier, Andreas
    INTERNIST, 2021, 62 (05): : 485 - 485
  • [34] Unlocking the Therapeutic Potential of Ellagic Acid for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
    Senavirathna, Tharani
    Shafaei, Armaghan
    Lareu, Ricky
    Balmer, Lois
    ANTIOXIDANTS, 2024, 13 (04)
  • [35] Other disease associations with non-alcoholic fatty liver disease (NAFLD)
    Allard, JP
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2002, 16 (05) : 783 - 795
  • [37] Fatty Liver Index (FLI) in Predicting Non-alcoholic Fatty Liver Disease (NAFLD)
    Dehnavi, Zahra
    Razmpour, Farkhonde
    Naseri, Mahmoud Belghaisi
    Nematy, Mohsen
    Alamdaran, Seyed Ali
    Vatanparast, Hassan Ali
    Nezhad, Mohsen Azimi
    Abbasi, Bita
    Ganji, Azita
    HEPATITIS MONTHLY, 2018, 18 (02)
  • [38] Therapeutic outcome of dapagliflozin on various parameters in non-alcoholic fatty liver disease (NAFLD) patients
    Hussain, Mazhar
    Babar, Muhammad Zafar Majeed
    Tariq, Saba
    Ahmad, Muhammad Irfan
    Akhtar, Lubna
    INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, 2022, 42 (02) : 290 - 296
  • [39] Therapeutic outcome of dapagliflozin on various parameters in non-alcoholic fatty liver disease (NAFLD) patients
    Mazhar Hussain
    Muhammad Zafar Majeed Babar
    Saba Tariq
    Muhammad Irfan Ahmad
    Lubna Akhtar
    International Journal of Diabetes in Developing Countries, 2022, 42 : 290 - 296
  • [40] HEPATOPROTECTIVE EFFECTS OF GARLIC AND ONION IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN RATS
    Ebeid, F.
    el-Din, Seif S.
    Sabra, A.
    Hammam, O.
    El-Lakkany, N.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 123 - 123